scholarly journals Prognostic Significance of the Proportion of Tall Cell Components in Papillary Thyroid Carcinoma

2017 ◽  
Vol 41 (10) ◽  
pp. 2644-2644 ◽  
Author(s):  
Sapana Bothra ◽  
Aromal Chekavar ◽  
Sabaretnam Mayilvaganan
2016 ◽  
Vol 41 (3) ◽  
pp. 742-747 ◽  
Author(s):  
Yasuhiro Ito ◽  
Mitsuyoshi Hirokawa ◽  
Akira Miyauchi ◽  
Takuya Higashiyama ◽  
Minoru Kihara ◽  
...  

Tumor Biology ◽  
2018 ◽  
Vol 40 (7) ◽  
pp. 101042831878772 ◽  
Author(s):  
Sebastian Stenman ◽  
Päivi Siironen ◽  
Harri Mustonen ◽  
Johan Lundin ◽  
Caj Haglund ◽  
...  

The subtype of the papillary thyroid carcinoma tall-cell variant has a worse prognosis than does the conventional papillary type (papillary thyroid carcinoma). The new World Health Organization 2017 classification defines a tall-cell variant as a tumour consisting of over 30% of cells that are two or three times as tall as they are wide. However, thresholds have differed. Our aim was to study how tall cells affect the prognosis of papillary thyroid carcinoma patients and to determine, for such cells, a cut-off percentage. Our cohort included 65 papillary thyroid carcinoma patients who underwent surgery at Helsinki University Hospital between 1973 and 1996: originally, 36 otherwise-matched patient pairs, eventually comprising 34 patients with an adverse outcome plus 31 who had recovered. All samples were digitally scanned and scored by two investigators based on tall cell composition. The cohort was analysed with four tall cell thresholds: 10%, 30%, 50% and 70% with a median follow-up of 22 years. In survival analysis, only the 70% threshold showed a correlation with reduced overall survival, disease-specific survival and relapse-free survival. A correlation also emerged with death from papillary thyroid carcinoma. In multivariate analysis, a 70% cut-off and age at diagnosis significantly affected DSS. Increasing tall cell score correlated with increasing age and extrathyroidal extensions. A tall cell composition of 10%, 30% or 50% showed no correlation with adverse outcome and suggests that the choice of pathologists reporting tall-cell variant should be a 70% threshold.


2007 ◽  
Vol 38 (2) ◽  
pp. 212-219 ◽  
Author(s):  
Jean Jacques Michels ◽  
Marnay Jacques ◽  
Michel Henry-Amar ◽  
Stephane Bardet

2020 ◽  
Vol 10 (1) ◽  
pp. 70
Author(s):  
Alessandro Longheu ◽  
Gian Luigi Canu ◽  
Federico Cappellacci ◽  
Enrico Erdas ◽  
Fabio Medas ◽  
...  

Background: The aim of this retrospective study was to investigate clinical and pathological characteristics of the tall cell variant of papillary thyroid carcinoma compared to conventional variants. Methods: The clinical records of patients who underwent surgical treatment between 2009 and 2015 were analyzed. The patients were divided into two groups: those with a histopathological diagnosis of tall cell papillary carcinoma were included in Group A, and those with a diagnosis of conventional variants in Group B. Results: A total of 35 patients were included in Group A and 316 in Group B. All patients underwent total thyroidectomy. Central compartment and lateral cervical lymph node dissection were performed more frequently in Group A (42.8% vs. 18%, p = 0.001, and 17.1% vs. 6.9%, p = 0.04). Angiolymphatic invasion, parenchymal invasion, extrathyroidal extension, and lymph node metastases were more frequent in Group A, and the data reached statistical significance. Local recurrence was more frequent in Group A (17.1% vs. 6.3%, p = 0.02), with two patients (5.7%) in Group A showing visceral metastases, whereas no patient in Group B developed metastatic cancer (p = 0.009). Conclusions: Tall cell papillary carcinoma is the most frequent aggressive variant of papillary thyroid cancer. Tall cell histology represents an independent poor prognostic factor compared to conventional variants.


2019 ◽  
pp. 225-228
Author(s):  
Miyoko Higuchi ◽  
Mitsuyoshi Hirokawa ◽  
Seiji Kuma

Author(s):  
Anello Marcello Poma ◽  
David Viola ◽  
Elisabetta Macerola ◽  
Agnese Proietti ◽  
Eleonora Molinaro ◽  
...  

Abstract Purpose Recent diagnostic criteria updates of the tall cell variant of papillary thyroid carcinoma (TCPTC) by the World Health Organization (WHO) have determined the inclusion of tumours with 30-49% of tall cells. However, the impact of tall cell percentage on papillary thyroid carcinoma (PTC) patients’ prognosis is still debated. We aimed to evaluate whether tall cell percentage affects patients’ outcome in the absence of aggressive features. Methods Rates of aggressive features, recurrence-free survival (RFS) and distant RFS (DRFS) (5-year median follow-up) were compared among tumours with less than 30%, 30-49% and at least 50% of tall cells. We also evaluated the impact of the new tall cell cut-off on patient management. Results Overall, 3092 tumours (15.7% of all PTC) were collected: 792 PTC had less than 30%, 503 had 30-49%, and 1797 had 50% or more tall cell areas. With the new definition of WHO, the number of TCPTC increased by 28%. There were no differences in recurrence rates according to tall cell percentage. The coexistence of BRAF and TERT promoter mutations predicted a worse RFS. Considering the new definition of TCPTC, the level of risk according to the American Thyroid Association increased from low to intermediate in 4.2% of cases. However, the recurrence rate within this subgroup was comparable to low-risk. Conclusions TCPTC and PTC with tall cell areas can be considered as a unique group with similar recurrence risk. However, whenever aggressive features are absent, tumors have a low risk of recurrence independently of tall cell percentage.


2018 ◽  
Vol 30 (1) ◽  
pp. 43-48 ◽  
Author(s):  
Kristine S. Wong ◽  
Sara E. Higgins ◽  
Ellen Marqusee ◽  
Matthew A. Nehs ◽  
Trevor Angell ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document